Indian Vaccine Fill-Finish Line MEP — WHO TRS 1019 + EU EMA Annex 1:2022 + USFDA 21 CFR 211 + Schedule M

By /
MEP Consultant · Vaccine Mfg · 12 May 2026

Indian Vaccine Fill-Finish Line MEP — WHO TRS 1019 + EU EMA Annex 1:2022 + USFDA 21 CFR 211 + Schedule M

Published: 08 May 2026Updated: 12 May 2026Original figures: 9

A 50-million-dose-per-year Indian vaccine fill-finish line demands ₹1,572 Cr MEP capex with Grade A in B isolator fill + Grade C wash + lyophiliser + WFI + pure steam + auto inspection + serialisation + cold storage. WHO TRS 1019 Annex 1 + EU EMA Annex 1:2022 + USFDA 21 CFR 211 + Schedule M 2023 + ICH Q8/9/10 govern. India vaccine capacity 5 billion doses/yr (2024) → 8B (2027). Three failures: EU Annex 1 2022 CCS + isolator updates not implemented, lyo SIP F0 not validated, EU FMD + India Track + Trace serialisation incomplete.

Indian vaccine fill-finish framework

Indian vaccine fill-finish — Serum Institute + Bharat Biotech + Biological E + Panacea + Indian Immunologicals + Cipla Biotech. Sterile aseptic filling of vaccine vials + syringes at Grade A LAF inside Grade B background. Standards stack — WHO TRS 1019 Annex 1 (sterile mfg) + EU EMA Annex 1:2022 + USFDA 21 CFR 211 Subpart D + ICH Q8/9/10 + USP 1116 + ISO 14644 + ISPE Baseline + India Schedule M 2023.

Vaccine fill-finish line MEP scope — 50 million dose/year

Zone Grade Function Capex (₹ Cr)
Vial washing + depyrogenation C wash + 350°C tunnel 85
Vial filling line (Grade A LAF in Grade B) A in B isolator-protected fill 485
Stoppering + capping A in B — 125
Visual inspection (auto + manual) D — 45
Labelling + cartoning + serialisation D EU FMD + India Track + Trace 85
Lyophiliser (freeze-dryer) A for lyophilised vaccines 220
Autoclave + decontamination — — 45
HVAC + AHU (Grade A/B/C/D separate) — — 185
Compressed air + N2 (medical grade) ISO 8573-1 Class 1 — 45
WFI Water for Injection — — 85
Pure steam — — 35
QC + microbiology + endotoxin lab — LAL + USP 1116 85
Cold storage (vaccine bulk + finished) -20°C + 2-8°C — 42
Total vaccine fill-finish line — — 1,572

Indian vaccine production capacity (billion doses/yr)Pre-COVID 20193.5B doses/yrCOVID peak 20214.5B doses/yr20224.8B doses/yr20235B doses/yr2024 (~5B)5.2B doses/yr2027 target (8B)8B doses/yr2030 (10B vision)10B doses/yrVaccine fill-finish capex (₹ Cr) — by annual production10M doses small485Cr50M doses (typical)1572Cr100M doses2850Cr300M doses5800Cr500M doses worldscale8500Cr1B doses (Serum-scale)14500Cr

Three Indian vaccine fill-finish MEP failures

  1. EU Annex 1 (2022) updated requirements not implemented — EU Annex 1 Aug 2023 implementation requires CCS (Contamination Control Strategy) + isolator vs RABS for high-risk + QRM. Indian exporters slow to adapt — face EMA inspection delays.
  2. Lyophiliser SIP (Steam-in-Place) not validated for thermal lethality — lyo chamber sterilisation requires F0 ≥ 15 min @ 121°C. Indian sites sometimes inadequate validation. WHO TRS 1019 + EU + USFDA inspection failure common.
  3. Track + trace serialisation EU FMD + India incomplete — EU Falsified Medicines Directive + India Track + Trace mandate unique 2D Datamatrix per vial. Indian exporters sometimes implement only one — face EU MDD rejection.
// References + Standards
  1. WHO TRS 1019 Annex 1 — Good Manufacturing Practices for Sterile Pharmaceutical Products.
  2. EU EMA Annex 1:2022 — Manufacture of Sterile Medicinal Products.
  3. USFDA 21 CFR 211 Subpart D + USP 1116.
  4. ICH Q8/Q9/Q10 — Pharmaceutical Development + Risk + Quality.
  5. ISO 14644 + ISPE Baseline Vol 5.
  6. Schedule M 2023 (India).
  7. EU FMD + India Track + Trace Mandate 2024.
  8. ICH Q1A — Stability.
By MEPVAULT Editorial Team — A team of practising MEP consultants based in India. ISHRAE-affiliated; FSAI-aligned.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top